Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1997-3-13
pubmed:abstractText
Alternative substrates of energy metabolism are thought to contribute to the impairment of heart and muscle glucose utilization in insulin-resistant states. We have investigated the acute effects of substrates in isolated rat cardiomyocytes. Exposure to lactate, pyruvate, propionate, acetate, palmitate, beta-hydroxybutyrate or alpha-oxoglutarate led to the depression of glucose transport by up to 50%, with lactate, pyruvate and propionate being the most potent agents. The percentage inhibition was greater in cardiomyocytes in which glucose transport was stimulated with the alpha-adrenergic agonist phenylephrine or with a submaximal insulin concentration than in basal or fully insulin-stimulated cells. Cardiomyocytes from fasted or diabetic rats displayed a similar sensitivity to substrates as did cells from control animals. On the other hand, the amination product of pyruvate (alanine), as well as valine and the aminotransferase inhibitors cycloserine and amino-oxyacetate, stimulated glucose transport about 2-fold. In addition, the effect of pyruvate was counteracted by cycloserine. Since reversible transamination reactions are known to affect the pool size of the citrate cycle, the influence of substrates, amino acids and aminotransferase inhibitors on citrate, malate and glutamate content was examined. A significant negative correlation was found between alterations in glucose transport and the levels of citrate (P < 0.01) or malate (P < 0.01), and there was a positive correlation between glucose transport and glutamate levels (P < 0.05). In contrast, there was no correlation with changes in [1-(14)C]pyruvate oxidation or in glucose-6-phosphate levels. Finally, pyruvate decreased the abundance of GLUT4 glucose transporters at the surface of phenylephrine- or insulin-stimulated cells by 34% and 27 % respectively, as determined by using the selective photoaffinity label [3H]ATB-BMPA [[3H]2-N-[4-(1-azi-2,2,2-trifluoroethyl)benzoyl]-1,3-bis-(D-man nos-4-yloxy)propyl-2-amine]. In conclusion, cardiomyocyte glucose transport is subject to counter-regulation by alternative substrates. The glucose transport system appears to be controlled by (a) compound(s) of intermediary metabolism (other than glucose 6-phosphate), but in a different way than pyruvate dehydrogenase. Transport inhibition eventually occurs via a decrease in the amount of glucose transporters in the plasma membrane.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-13728679, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-13772576, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-13990765, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-14073034, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-1601987, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-16742828, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-1710451, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-1943473, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2026747, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2123803, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2213603, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2221110, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2390055, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2396984, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2804076, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-2890259, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-3185286, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-3289989, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-3292587, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-3401217, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-4087305, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-4220952, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-4316090, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-4329775, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-4774128, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-4839051, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-5085551, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-5449122, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-5766656, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-5775879, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-5839199, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-6208788, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-6386058, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-6430348, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-6876186, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-701258, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-7115698, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-7306575, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-7487898, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-7835271, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-7929613, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-8163056, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-8166252, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-8349666, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-8428713, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-8660623, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-8928747, http://linkedlifedata.com/resource/pubmed/commentcorrection/9032447-8928748
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/3-Hydroxybutyric Acid, http://linkedlifedata.com/resource/pubmed/chemical/3-O-Methylglucose, http://linkedlifedata.com/resource/pubmed/chemical/Deoxyglucose, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Glucose, http://linkedlifedata.com/resource/pubmed/chemical/Glucose Transporter Type 1, http://linkedlifedata.com/resource/pubmed/chemical/Glucose Transporter Type 4, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxybutyrates, http://linkedlifedata.com/resource/pubmed/chemical/Insulin, http://linkedlifedata.com/resource/pubmed/chemical/Lactic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Monosaccharide Transport Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Muscle Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Phenylephrine, http://linkedlifedata.com/resource/pubmed/chemical/Pyruvic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Slc2a4 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Transaminases
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
321 ( Pt 3)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
629-38
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
More...